Croissy-Beaubourg and Montpellier, June 4, 2013 Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announced that it is significantly strengthening its activities in microRNA.
Theradiag has signed a partnership agreement with the Regional Cancer Institute of Montpellier (ICM) to develop microRNA-based theranostics tools for the screening and monitoring of colorectal cancer.
The goal of the collaborative R&D program called miCRA is to assess the expression and predictive role of microRNA in treatment response to radio/chemotherapies for colorectal cancer. As part of the project, Theradiag will identify relevant biomarkers and develop related theranostic assays.
In parallel, Theradiag is proud to announce the opening of its new laboratory dedicated to applied research for the development of microRNA-based assays within the Cap Alpha incubator in Montpellier. Guillaume Veter, lab director and microRNA specialist, along with a technician will strengthen the existing teams of Theradiag¹s 100% subsidiary Prestizia. They will work in close collaboration with the French National Scientific Research Council (CNRS) team dedicated to Theradiag.
"We are pleased to welcome such an experienced team, and to have signed a very promising third partnership agreement with the ICM. This integrated laboratory and this new agreement strengthen our positioning in microRNA and theranostic tools for cancerology. They come in addition on to our ongoing miRNA projects in HIV/AIDS with the CNRS and Splicos and allow us to expand our theranostic portfolio to a broader range of diseases. Early detection and care of patients through individualized monitoring and treatment are critical success factors of most therapies. These developments validate our theranostic strategy for personalized medicine" said Michel Finance, CEO of Theradiag.
Created in 1923, the Regional Cancer Institute of Montpellier (ICM) is now recognized as of the leading national centers for cancer patient care, as well as the reference regional center for cancer patients in the Languedoc Roussillon area (with over 40 000 consults and 26 000 patients treated per year). The ICM is part of the 18 Cancer Centers (CLCC) of the UNICANCER group, the first hospital group fully dedicated to cancerology with over 900 employeed including 105 doctors, 11 research teams and 140 researchers. The ICM is is one of 8 research centers in France to have received the Integrated Research Center of Cancer (SIRIC) mark, as well as one of France's leading research CLCCs (clinical, fundamental and translational research).
Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Tél: 01 64 62 10 12